Predicting the risk of chest radiograph abnormality 12-weeks post hospitalisation with SARS CoV-2 PCR confirmed COVID-19

Tim JM Wallis, Benjamin Welham, Alex Kong, Tommaso Morelli, Adnan Azim, Jose Horno, Miranda Wilkinson, Hannah Burke, Anna Freeman, Thomas MA Wilkinson, Mark G Jones and Benjamin G Marshall

Abstract

Background Routine follow-up of patients hospitalised with COVID-19 is recommended, however due to the ongoing high number of infections this is not without significant health resource and economic burden. In a previous study we investigated the prevalence of, and risk factors for, persistent chest radiograph (CXR) abnormalities post-hospitalisation with COVID-19 and identified a 5-point composite score that strongly predicted risk of persistent CXR abnormality at 12-weeks. Here we sought to validate and refine our findings in an independent cohort of patients.

Methodology A single-centre prospective study of consecutive patients attending a virtual post-hospitalisation COVID-19 clinic and CXR as part of their standard clinical care between 2nd March – 22nd June 2021. Inpatient and follow-up CXRs were scored by the assessing clinician for extent of pulmonary infiltrates (0–4 in each lung) with complete resolution defined as a follow-up score of zero.

Results 182 consecutive patients were identified of which 31% had persistent CXR abnormality at 12-weeks. Patients with persistent CXR abnormality were significantly older (p < 0.001), had a longer hospital length of stay (p = 0.005), and had a higher incidence of both level 2 or 3 facility admission (level 2/3 care) (p = 0.003) and ever-smoking history (p = 0.038). Testing our composite score in the present cohort we found it predicted persistent CXR abnormality with reasonable accuracy (area under the receiver operator curve [AUROC 0.64]). Refining this score replacing obesity with Age ≥ 50 years, we identify the SHADE-750 score (1-point each for: Smoking history, Higher-level care (level 2/3 admission), Age ≥ 50 years, Duration of admission ≥ 15 days and Enzyme-lactate dehydrogenase (LDH ≥ 750U/L), that accurately predicted risk of persistent CXR abnormality, both in the present cohort (AUROC 0.73) and when retrospectively applied to our 1st cohort (AUROC 0.79). Applied to both cohorts combined (n = 213) it again performed strongly (AUROC 0.75) with all patients with a score of zero (n = 18) having complete CXR resolution at 12-weeks.
Conclusions  In two independent cohorts of patients hospitalised with COVID-19, we identify a 5-point score which accurately predicts patients at risk of persistent CXR abnormality at 12-weeks. This tool could be used by clinicians to identify patients in which radiological follow-up may not be required.

Keywords  COVID-19, SARS-CoV-2, Chest radiograph, LDH

Background
Despite novel COVID-19 treatments and vaccines, the COVID-19 pandemic continues with high levels of infection and there is now appreciation in the scientific community that the COVID-19 pandemic will end with the severe acute respiratory syndrome coronavirus – 2 (SARS CoV-2) virus becoming endemic [1]. National and international guidelines have been published outlining follow-up strategies for patients hospitalised with COVID-19 [2, 3]. Current British Thoracic Society (BTS) guidance recommends a follow-up chest radiograph (CXR) at 12-weeks for all patients hospitalised with COVID-19 pneumonia [3] to monitor for potential long term sequelae such as post-COVID fibrosis [4]. Since implementation of these guidelines, studies have identified persistent CXR abnormality in 13–38% of COVID-19 survivors at 2–3 month follow-up [5–7].

As a consequence of the ongoing high-rate of infection the follow-up of patients hospitalised with COVID-19 has a significant and ongoing health resource and economic burden [8, 9]. Hence there is clinical need for the development of prognostic tools which aid triage of patients into those who require routine follow-up and those where it may not be necessary.

In a previous article, [7] we described outcomes of a prospective study of patients hospitalised during the U.K 1st wave of the COVID-19 pandemic (March-June 2020) attending virtual follow-up. In this article 32% of patients had persistent CXR abnormality at 12-weeks and using a five-point composite model (1-point each for; hospital length of stay ≥ 15 days, Level 2 or 3 care facility admission, admission lactate dehydrogenase [LDH] ≥ 750 U/L, obesity, and ever smoking-status) strongly predicted patients at risk of persistent abnormality (area under the receiver operating characteristic curve [AUROC] 0.81).

In this study we sought to validate and refine the risk score in an independently recruited second cohort of patients. With the aim of testing how accurately it could identify a group of patients who do not require routine CXR follow up following hospitalisation with SARS CoV-2 infection.

Methods
This was a prospective cohort study at a single academic medical centre, University Hospital Southampton NHS Foundation Trust (UHSFT). The present cohort comprised consecutive patients hospitalised with PCR confirmed symptomatic SARS CoV-2 infection attending for a 12-week virtual follow-up clinic and CXR as part of their standard clinical care between 2nd March – 22nd June 2021. Ethical approval was obtained from the South-Central Hampshire A Research Ethics Committee (REC reference (20/SC/0138) as part of the REACT study (REal-time Analytics for Clinical Trials observational study of COVID-19). Informed consent was waived because of the study design.

The general methodology for the study is as previously described [7]. Briefly, baseline and 12-week follow-up CXRs were scored for COVID-19 related pulmonary infiltrates by the assessing clinician at the virtual follow-up appointment from 0 to 4 for each lung (0 = nil, 1 = < 25%, 2 = 25–50%, 3 = 51–75%, 4 = ≥ 75%) [10]. The baseline CXRs were defined as the last film prior to patient’s discharge (or the admission film if only one radiograph was performed). This was either a postero-anterior (PA) or anteroposterior (AP) film as performed during standard of care. Follow-up outpatient films were all departmental PA chest radiographs.

Level 2 care was defined as patients requiring single organ support excluding mechanical ventilation (High dependency unit) and level 3 care those requiring mechanical ventilation alone or two or more organ support (Intensive care unit).

Baseline and 12-week follow-up LDH samples were taken as part of routine standard clinical care and analysed at UHSFT. Here, continuous data is presented as the median and interquartile range (IQR) with comparisons between data made using the Mann Whitney U-test and Chi-squared test (χ2) as appropriate. Association between continuous variables was assessed using Spearman’s correlation coefficient (r). Model discrimination is presented using the area under the receiver operating characteristic curve (AUROC). We first tested the performance of our previously published 5-point composite score. This score was then revised and re-tested with the aim of increasing its performance based on associated risk factors identified in the present study. P values of < 0.05 were deemed significant. Statistical analysis was conducted using IBM®-SPSS® (version 26).

Results
One-hundred and eighty-two (n = 182) consecutive patients were identified 54% of which were male. The median (IQR) hospital length of stay was 9 days [8–13] and median CXR follow-up interval was 80 days (74–96) (Table 1). Compared to our previous study, patients in
Table 1  Baseline characteristics for present study cohort (n = 182). Comparing those with complete chest radiograph resolution (n = 126) versus those with persistent abnormality (n = 56). Values presented as median (interquartile range) for continuous variables and percentage (n) for categorical variables. CXR-chest radiograph, Level 2 - High Dependency Facility, Level 3-Intensive Care Facility, IMV- Invasive mechanical ventilation, CPAP-continuous positive pressure ventilation, NIV – non-invasive ventilation, BAME - Black, Asian and Minority Ethnic. BMI body mass index (kg/m^2), LDH- serum lactate dehydrogenase. ^data available for baseline LDH n = 165 and follow-up LDH n = 172. *p < 0.05 **p < 0.01.

Comparison of data for complete resolution versus persistent CXR abnormality assessed using the Mann-Whitney U Test or Chi Squared test as appropriate.

| Variable                        | Whole Group (n=182) | Complete Resolution (n=126) | Persistent CXR Abnormality (n=56) | p value |
|---------------------------------|---------------------|----------------------------|-----------------------------------|---------|
| Sex (male)                      | 54% (n=98)          | 51% (n=64)                 | 61% (n=34)                        | 0.235   |
| Age (years)                     | 58.0 (47–67)        | 55.0 (45–64)               | 64.0 (54–74)                      | <0.001**|
| Hospital length of Stay (days)  | 9.0 (8–13)          | 7.0 (4–12)                 | 10.5 (7–16)                       | 0.005** |
| Follow-up CXR interval (days)   | 80.0 (74–86)        | 81.0 (75–86)               | 79.0 (72–85)                      | 0.144   |
| Level 2 or 3 Care               | 31% (n=57)          | 25% (n=31)                 | 46% (n=26)                        | 0.003** |
| IMV                             | 8% (n=15)           | 8% (n=10)                  | 9% (n=5)                          | 0.822   |
| CPAP/NIV                        | 24% (n=43)          | 16% (n=20)                 | 41% (n=23)                        | <0.001**|
| Oxygen or higher resp. support  | 92% (n=167)         | 90% (n=114)                | 95% (n=53)                        | 0.345   |
| BAME                            | 27% (n=47)          | 29% (n=35)                 | 23% (n=12)                        | 0.407   |
| Obesity (BMI > 30 kg/m^2)       | 40% (n=72)          | 42% (n=53)                 | 34% (n=19)                        | 0.300   |
| Ever smoker                     | 44% (n=80)          | 39% (n=49)                 | 55% (n=31)                        | 0.038*  |
| Hypertension                    | 23% (n=42)          | 25% (n=31)                 | 20% (n=11)                        | 0.464   |
| Diabetes Melitus (all types)    | 20% (n=37)          | 22% (n=28)                 | 16% (n=9)                         | 0.341   |
| Baseline LDH U/L^               | 643 (506–854)       | 626 (501–830)              | 667 (535–959)                     | 0.240   |
| Follow-up LDH U/L^              | 387 (348–449)       | 379 (329–443)              | 407 (367–456)                     | 0.032*  |
the present study were non-significantly older (median 58 years vs. 54 years p=0.07), had a higher incidence of obesity (40% vs. 28% p=0.03) and a lower incidence of hypertension (23% vs. 35% p=0.03). Furthermore, a lower proportion of patients had a level 2/3 care facility admission (31% vs. 49% p<0.01), this reflecting the enrichment of our previous study cohort for patients requiring higher level care (Supplemental Table 1).

At the 12-week virtual follow-up, the most common persistent symptoms in the present study were dyspnoea in 39% and fatigue in 35%. 73% (73%) of patients were discharged following their 12-week virtual appointment.

The median CXR scores at baseline and 12-week follow-up were 5.0 [3–6] and 0.0 (0–1) respectively. Persistent CXR abnormality (score≥1) was present in 31% (n=56) of the cohort at 12-weeks, in whom 30% (n=17) had an infiltrate score of 1, 39% (n=22) a score of 2, and 30% (n=17) a score of 3 or more (Supplemental Fig. 1).

Compared to those with complete resolution, patients with persistent CXR abnormality were significantly older (64 years vs. 55 years p<0.001), had longer hospital length of stay (10.5 days vs. 7.0 days p<0.01), and had a higher incidence of both level 2/3 care facility admission (46% vs. 25% p<0.01) and ever-smoking history (55% vs. 39% p=0.04). There was no statistical difference between patients with persistent abnormality and complete resolution for requirement of supplemental oxygen, obesity, or CXR follow-up interval.

No significant between group difference was observed in baseline LDH (667 U/L vs. 626 U/L p=0.24) (Table 1), or significant correlation observed between baseline LDH and follow-up CXR score (r=0.06 p=0.49). However, follow-up LDH was significantly higher in patients with persistent CXR abnormality (406 U/L vs. 379 U/L p=0.03). In addition, baseline LDH was significantly positively correlated with baseline CXR scores (r=0.23 p=0.01) and follow-up LDH concentrations (r=0.33 p<0.001), whereas follow-up LDH was significantly correlated with both baseline (r=0.26 p<0.01) and follow-up CXR score (r=0.20 p<0.01).

Testing our previously published 5-point score, we found it predicted patients at risk of persistent CXR abnormality with reasonable accuracy in this cohort, AUROC 0.64 (95% confidence interval [CI] 0.54–0.72) p=0.047. In the present cohort obesity was not associated with persistent CXR abnormality and this factor detracted from the score performance. As age is a key risk factor for disease severity in COVID-19 [11], and in the present study associated with persistent CXR abnormality, in our present study we tested an adapted 5-point score replacing obesity with patient age. Using a stratification of age≥50 years we developed the SHADE-750 score (1-point each for: Smoking history, Higher-level care (level 2/3 admission), Age≥50 years, Duration of admission≥15 days and Enzyme-LDH≥750 U/L) (Fig. 1a). This adapted 5-point score accurately predicted risk of persistent abnormality in this cohort, AUROC 0.73 (95%CI 0.65–0.82) p<0.0001 (Fig. 1b). Retrospective application of this adapted score to our 1st wave cohort identified that it also had strong discrimination, AUROC 0.79 (95%CI 0.68–0.90) p<0.0001 (Fig. 1c). When applying the adapted model to both cohorts combined (n=213) it again performed strongly (AUROC 0.75 [95%CI 0.69–0.82] p<0.0001) (Fig. 1d). Furthermore, in this combined analysis, persistent CXR abnormality was not identified in any patients with a combined score of 0 (n=18 with score, negative predictive value [NPV] 100%), and was present in only 4 patients with a score of 1 (n=43 with score, NPV of score 0–1 94%).

Discussion

In this prospective cohort study, we confirm previous observations that persistent CXR abnormality is present in approximately 30% of patients hospitalised with COVID-19 at 12-week follow-up. Furthermore, in two independent cohorts of patients we identify a 5-point risk stratification tool, the SHADE-750 score, that accurately predicted patients at risk of persistent CXR abnormality at 12-weeks. In combined analysis (n=213), persistent CXR abnormality was not identified in any patients with a combined score of zero and we propose that this score could be used to accurately identify a group of patients for which routine radiological follow-up is not required.

The rate of persistent CXR abnormality identified in the present study is similar to that observed in previous reports.[5–7] Our finding that hospital length-of-stay and higher-level respiratory support are associated with persistent radiological abnormality at the 3 month follow-up timepoint is consistent with results of prospective studies using computed-tomography (CT) scanning [12, 13]. Our observation that age and smoking are associated with persistent CXR abnormality is consistent with both factors being associated with increased risk of greater COVID-19 disease severity [11, 14].

LDH is a non-specific marker of tissue inflammation and elevated LDH is associated with disease severity [15] and acute respiratory distress syndrome in COVID-19 [16]. In our previous study we observed significantly higher baseline LDH concentrations in patients with persistent CXR abnormality, an observation we failed to replicate in the present study. An important factor to consider is, whilst not standard care early in the COVID-19 pandemic, patients in the present study requiring supplemental oxygen would have received treatment with dexamethasone unless contraindicated [17]. Consistent with our previous observations follow-up LDH was significantly higher in those with persistent CXR abnormality and further baseline LDH significantly correlated...
Fig. 1 Area under receiver operating curve for risk of persistent chest radiograph abnormality using the ‘SHADE-750’ 5-point risk stratification score. (A) SHADE-750 score (1-point each for; Smoking history (Ever vs. Never), H igher-level care (level 2 or 3 care admission), A ge ≥50 years, D uration of admission ≥15 days and E nzyme-lactate dehydrogenase [LDH] ≥750U/L). (B) Present study cohort (2nd Wave cohort) n = 147 with available data for score, of which persistent CXR abnormality n = 46 and complete resolution n = 101. (C) Previous study 1st Wave cohort (Wave 1) n = 66 with available data for score, of which persistent CXR abnormality n = 23 and complete resolution n = 43. (D) Present study and previous study cohorts combined (Wave 1 and 2) n = 213 with available data for score, of which persistent CXR abnormality n = 69 and complete resolution n = 144.
with follow-up LDH concentrations. It may be that delayed normalisation of LDH reflects ongoing lung tissue inflammation/injury [18]. A hypothesis that would require testing in a formal mechanistic study.

The moderate performance of our original 5-point score, and poor discrimination of obesity, in the present study may relate to the inherent differences between the two study cohorts including, the introduction of standard of care COVID-19 therapies, the emergence of SARS CoV-2 variants [19], and the COVID-19 vaccination programme in the UK [20]. A further limitation we noted was that our 1st wave cohort was enriched for patients admitted to level 2/3 care, reflecting clinical prioritisation in response to an emerging global pandemic, whereas the present study consisted of all hospitalised patients attending a dedicated follow-up service.

This study has limitations. In our established methodology, chest radiographs were not dual reported, hence it is not possible to assess concordance between assessors. However, we believe this increases the real-world applicability of our observations. Second, the score was designed to identify those at risk of persistent CXR abnormality, with its negative predictive value then appreciated. This construct may increase the scores clinical utility by reducing the impact of any missing clinical data. As once a threshold is reached further data does not alter score outcome (e.g., follow-up not required vs. follow-up recommended). A further limitation is that, due to lack of available data, it was not possible to control for any impact of patient vaccination status, SARS CoV-2 variants, or use of targeted COVID-19 therapies on the results. However, despite the differences in the disease and available treatments between cohorts, our revised score performed strongly in both. Within this study design we cannot definitively predict whether patients with CXR abnormality at 12-weeks will develop lasting radiological pathology. Although, in the present analysis we identify a group of patients in which routine radiological follow-up may not be required. Future research should focus on investigating the utility of this, or other identified predictive models, on persistent symptoms following COVID-19 infection.

In conclusion we identify, in two independent cohorts of patients hospitalised with COVID-19, a 5-point scoring system which accurately predicts patients at risk of persistent CXR abnormality at the 12-week timepoint. This score could be used as a tool to aid clinicians in triaging a group of patients that do not require routine radiological follow-up. External validation of these observations is required.

**List of abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| BMI          | body mass index (kg m⁻²) |
| AUROC        | area under the receiver operating characteristic curve |
| 95%CI        | 95% Confidence interval |
| CT           | computerised tomography |
| CXR          | chest radiograph |
| HR           | Hazard Ratio |
| IQR          | interquartile range |
| LDH          | Lactate dehydrogenase |
| Level 2      | High dependency facility |
| Level 3      | Intensive care facility |
| LOS          | Length of hospital stay |
| SARS CoV-2   | Severe acute respiratory syndrome coronavirus 2 |
| PCR          | Polymerase chain reaction |
| UHSFT        | University Hospitals Southampton NHS Foundation Trust |

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12931-022-02217-0.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

TW constructed and executed the data analysis plan.

TW, MG and BW drafted the manuscript.

TW, BW, AK, TM, JH, MW, MJ, BGM collected data and drafted final manuscript.

HR, AF, TNMW designed the Southampton REACT study and drafted final manuscript.

All authors reviewed and agreed the final manuscript for submission.

**Funding**

TJMW and BGM received an NHS Charities Together Grant which supported this work. The corresponding author TJMW receives a research fellowship grant from the NIHR Southampton Clinical Research Facility (Southampton, UK).

**Data availability**

All data generated or analysed during this study are included in this published article [and its supplementary information files].

**Declarations**

**Ethics approval and consent to participate**

The study was approved by the South-Central Hampshire A Research Ethics Committee: REC reference 20/SC/0138, on the 16th March 2020. No patient identifiable data is included in this manuscript. Informed consent was waived due to the study design.

**Consent for publication**

Consent for inpatient chest radiograph images [contained in the Supplemental File] was obtained through the REACT study (REC. 20/SC/0138).

**Competing interests**

The authors have no competing interests to declare.

**Author details**

1Department of Respiratory Medicine and Southampton NIHR Biomedical Research Centre, School of Clinical and Experimental Sciences, Faculty of Medicine, University Hospital Southampton, University of Southampton, Southampton, UK

2Department of Respiratory Medicine, University Hospital Southampton, Southampton, UK

**Received:** 25 February 2022 / **Accepted:** 9 October 2022

**Published online:** 31 October 2022
References

1. Phillips N. The coronavirus is here to stay—here’s what that means. Nature. 2021;590(7846):382–4.
2. Raghu G, Wilson KC. COVID-19 interstitial pneumonia: monitoring the clinical course in survivors. Lancet Respir Med. 2020;8(9):839–42.
3. British Thoracic Society. British Thoracic Society guidance on respiratory follow up of patients with a clinico-radiological diagnosis of COVID-19 pneumonia V1.2. BTS. 2020 https://www.brit-thoracic.org.uk/covid-19/covid-19-information-for-the-respiratory-community/. [Accessed 27th Jan 2022 2020].
4. McDonald LT. Healing after COVID-19: are survivors at risk for pulmonary fibrosis? Am J Physiology-Lung Cell Mol Physiol. 2020;320(2):L257-L65.
5. Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76(4):396–8.
6. Arnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021;76(4):399–401.
7. Wallis TJM, Heiden E, Horro J, Welham B, Burke H, Freeman A, et al. Risk factors for persistent abnormality on chest radiographs at 12-weeks post hospitalisation with PCR confirmed COVID-19. Respir Res. 2021;22(1):157.
8. Menges D, Ballouz T, Anagnostopoulos A, Aschmann HE, Domenghino A, Fehr JS, et al. Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study. PLoS ONE. 2021;16(7):e0254523-e.
9. Horby P, Emberson WLJ, Maffham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianovskii A, Prudon EE, Green C, Fenton T, Chadwick D, Rege K, Fegan C, Chappell LC, Jaki SFT, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R M, for The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020;382(18):693–704.
10. McFadden RG, Oliphant LD. Serum Lactate Dehydrogenase in Interstitial Lung Disease: To the Editor. Chest. 1991;100(4):1182.
11. Challen R, Brooks-Pollock E, Read J, Dyson L, Tsiang-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021;372:n579.
12. Wu X, Liu X, Zhou Y, Yu H, Li R, Zhan Q, et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021;9(7):747–54.
13. Clark AK, von Ande A, Tan PS, Sallis HM, Lindsen N, Coupland CAC, et al. Smoking and COVID-19 outcomes: an observational and Mendelian randomisation study using the UK Biobank cohort. Thorax. 2022;77(1):65–73.
14. Guan WJ, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708–20.
15. Figueira Gonçalves JM, Hernández Pérez JM, Acosta Sorensen M, Wangüemert Pérez AL, Martin de la Rosa R, Trujillo Castilla EJL, et al. Biomarkers of acute respiratory distress syndrome in adults hospitalised for severe SARS-CoV-2 infection in Tenerife Island, Spain. BMC Research Notes. 2020;13(1):SS5.
16. Challen R, Brooks-Pollock E, Read J, Dyson L, Tsiang-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021;372:n579.
17. Carlin J, Wallis TJJ, Jeyarajah A, Linsell L, Brightling C, Ustianovskii A, Prudon EE, Green C, Fenton T, Chadwick D, Rege K, Fegan C, Chappell LC, Jaki SFT, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R M, for The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020;382(18):693–704.
18. McFadden RG, Oliphant LD. Serum Lactate Dehydrogenase in Interstitial Lung Disease: To the Editor. Chest. 1991;100(4):1182.
19. Challen R, Brooks-Pollock E, Read J, Dyson L, Tsiang-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021;372:n579.
20. Bariunck C. Covid-19: How the UK vaccine rollout delivered success, so far. BMJ. 2021;372:n421.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.